The small, 48-subject study – published ... in Boston is running a four-week pilot study comparing Eli Lilly's dual GIP/GLP-1 tirzepatide to placebo in around 20 AUD patients, focusing on ...

Eli Lilly wants to take big swings in Alzheimer’s, ALS, chronic pain and other difficult diseases after its success in ...

Ascletis Pharma’s rapid-fire expansion into obesity drug development has passed another milestone. | Ascletis Pharma’s ...

Altimmune's existence depends almost entirely on the outcome of the Phase 2 trial for pemvidutide in MASH. Learn why ALT ...

The Hong Kong company saw a reduction in body weight across both cohorts with no serious adverse events reported.

Pharm Exec’s 20th Annual Pipeline Report examines the emerging drug development trends and surging investments in five ...

According to the companies the molecule ... Eli Lilly, Hanmi is working with some other big names in the pharma industry. It is working with Sanofi on a next-generation long-acting GLP-1 diabetes ...

Healthcare costs and spending have been rising in the US. The Centers for Medicare & Medicaid Services reported that ...

1 Eli Lilly and ... and $61.0 billion. Eli Lilly and Company (NYSE: LLY) and Scorpion Therapeutics, Inc. ("Scorpion"), a private biotechnology company developing small molecule precision oncology ...

Baron Funds, an investment management company, released its “Baron Health Care Fund” fourth quarter 2024 investor letter. The ...

Eli Lilly Chief Scientific Officer Dan Skovronsky spoke to CNBC about obesity pills and more on the future of weight loss.

CardCash.com to Offer Cost-Effective Solutions for High-Demand GLP-1 Medications as Prescription Drug Market GrowsSCHAUMBURG, IL, Feb. 20, 2025 ...